12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kappaproct: Phase III started

InDex began the double-blind, placebo-controlled, European Phase III COLLECT trial to evaluate 2 rectal doses of 30 mg Kappaproct given 2 weeks apart as add-on to standard therapy in about 120 UC patients...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >